HAE
HAEMONETICS CORP
Latest close $83.60 as of Aug 5, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 6 parsed filing(s) · 3 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management CIK0001897612 | Mar 31, 2025 observed May 14, 2025 filed · 44d Schedule 13G amendment | Earliest Schedule 13G amendment found | 2.2M | 12.00% | $63.55 | $68.65 | $83.60 |
| Capital Research Global Investors CIK0001422848 | Mar 31, 2025 observed Apr 4, 2025 filed · 4d Schedule 13G amendment | Reported accumulation | 50.2M +45.8M | 12.00% +3.30 pts | $63.55 | $60.88 | $83.60 |
| Capital Research Global Investors CIK0001422848 | Sep 30, 2024 observed Nov 12, 2024 filed · 43d Schedule 13G amendment | Reported reduction | 4.4M -2.1M | 8.70% -4.20 pts | $83.60 |